公开(公告)号：EP3778538A1

公开(公告)日：2021-02-17

申请号：EP19785608.1

申请日：2019-04-12

申请人： Hinova Pharmaceuticals Inc.

发明人： DU, Wu ,  WEN, Kun ,  HE, Jinyun ,  LI, Haibo ,  QIN, Dekun ,  LI, Xinghai ,  CHEN, Yuanwei

IPC分类号： C07B43/06 ,  C07D233/86 ,  C07D401/04 ,  C07D401/06 ,  C07C231/10 ,  C07C233/65 ,  C07C233/58 ,  C07C233/11 ,  C07C233/05

摘要： Disclosed is a novel method for synthesizing deuterated amides and deuterated sulfonamides, the steps being as follows: (1) adding a compound M, DMAP, R 3 -X to a solvent to obtain a compound N after a reaction is complete; (2) adding the compound N, R 4 -NH-R 5 , or a salt and base thereof to a solvent, and purifying after a reaction is complete to obtain a compound I. The method has mild reaction conditions and a short synthesis route, and a product may be obtained in only two steps; the method may be applied to raw materials which are not suitable for existing methods, and may increase synthesis efficiency; the method may be suitable for many amide compounds, has strong universality, and provides a novel option for the preparation of deuterated amide and sulfonamide compounds.

公开(公告)号：EP3683214A1

公开(公告)日：2020-07-22

申请号：EP18855304.4

申请日：2018-09-14

申请人： Hinova Pharmaceuticals Inc.

发明人： FAN, Lei ,  XU, Kexin ,  CHEN, Ke ,  WANG, Fei ,  WU, Xiaoquan ,  LUO, Tongchuan ,  ZHANG, Shaohua ,  LI, Xinghai ,  CHEN, Yuanwei

IPC分类号： C07D401/14 ,  C07D239/91 ,  A61K31/517 ,  A61K31/553 ,  A61K31/555 ,  A61P35/00 ,  A61P29/00

摘要： Disclosed is a BRD4 inhibitor as shown in formula I, belonging to the field of compound drugs. The compound provided has a good inhibitory effect on prostate cancer cell proliferation, and can be used for preparing a drug combatting tumors, autoimmune or inflammatory diseases and viral infection, and in particular an anti-prostate cancer drug.

公开(公告)号：EP3527556A1

公开(公告)日：2019-08-21

申请号：EP16919556.7

申请日：2016-12-20

申请人： Hinova Pharmaceuticals Inc.

发明人： CHEN, Yuanwei ,  DU, Wu ,  KUANG, Tongtao ,  GENG, Xi

IPC分类号： C07D233/86 ,  C07B59/00

摘要： The present invention discloses a method for preparation of deuterated imidazole diketone compounds, that includes the following steps: (1) using compound of formula (I) and compounds of formula (II) as starting material, compounds of formula (III) are obtained by a substitution reaction; (2) Compounds of formula (IV) are prepared by esterification of carboxyl in compounds of formula (III); (3) Cyclization of compounds of formula (IV) and compound of formula (V) provides compounds of formula (VI); (4) Compounds of formula (VI) are deesterificated and react to produce compounds of formula (VII); (5) using compounds of formula (VII) and compounds of formula (VIII) as starting material, the deuterated imidazole diketone compounds of formula (IX) are obtained by the condensation reaction of amide. Compared with the methods in the prior art, the method according to the present invention is safer, consuming less solvents, minimizing the waste and the effect on the environment, shortening the production cycle, and improving the throughput and the total yield of the method, with a wide market outlook.

公开(公告)号：EP3950678A1

公开(公告)日：2022-02-09

申请号：EP20784231.1

申请日：2020-03-31

申请人： Hinova Pharmaceuticals Inc.

发明人： DU, Wu ,  LV, Haibin ,  QIN, Dekun ,  LI, Haibo ,  LI, Yu ,  TU, Zhilin ,  CHEN, Yuanwei ,  LI, Xinghai

IPC分类号： C07D231/12 ,  C07D261/08 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D417/12 ,  C07D498/04 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/423 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/4355 ,  A61P35/00

摘要： Provided are an aromatic amine compound and a use thereof in the preparation of AR and BRD4 dual inhibitors and regulators. Specificially provided is the the compound shown in formula I, said compound having dual inhibitory effects on AR and BRD4. The compound is not only capable of inhibiting the proliferation of androgen receptor AR multi-expressed prostate cancer cell line LNCAP/AR, but also shows good inhibitory effects on prostate cancer lines VCaP and RRRV1 which are resistant to prostate cancer drugs (enzalutamide) on the market. The compound is itself a compound capable of simultaneously identifying AR and BRD4 dual targets and can be used as a dual AR/BRD4 inhibitor, and is also capable of being used for preparing proteolysistargeting chimeras (PROTACs) for inducing the degradation of AR/BRD4 dual targets, and has good propects for application in the preparation of drugs for the treatment of AR and BRD4-related diseases.

公开(公告)号：EP3795153A1

公开(公告)日：2021-03-24

申请号：EP19803519.8

申请日：2019-05-13

申请人： Hinova Pharmaceuticals Inc.

发明人： WEI, Xing ,  QI, Ming ,  DU, Wu ,  LI, Xinghai ,  CHEN, Yuanwei

IPC分类号： A61K31/4166 ,  A61K9/48 ,  A61P35/00

摘要： Provided is a formulation of androgen receptor inhibitor HC-1119 prepared from the following raw materials at the weight ratio: 1 to 100 parts of the androgen receptor inhibitor HC-1119, 100 to 1000 parts of a solvent, and 0.11 to 11 parts of an antioxidant. Also provided is a HC-1119 soft capsule and a HC-1119 formulation. The HC-1119 raw material is dissolved in Labrasol so as to significantly improve the solubility of HC-1119, and thus greatly improve the bioavailability, reduce the difference in blood drug concentration and exposure among individuals, and increase the safety of medication. Further, the HC-1119 soft capsule has good stability.

公开(公告)号：EP3730484A1

公开(公告)日：2020-10-28

申请号：EP18890728.1

申请日：2018-12-20

申请人： Hinova Pharmaceuticals Inc.

发明人： DU, Wu ,  AI, Chaowu ,  LI, Yu ,  WEN, Kun ,  LV, Haibin ,  REN, Wen ,  HE, Jinyun ,  QIN, Dekun ,  LI, Xinghai ,  CHEN, Yuanwei

IPC分类号： C07D271/08 ,  C07D413/12 ,  A61P27/12 ,  A61P25/00 ,  A61P37/02 ,  A61K31/4245 ,  A61P35/00

摘要： Provided is a compound represented by formula (I). Also provided are a pharmaceutical composition containing the compound of formula (I) and use of the compound in preparing indoleamine-2,3-dioxygenase (IDO) inhibitor drugs. The compound or the pharmaceutical composition thereof can be used for preparing drugs for preventing and/or treating diseases having pathological features of IDO-mediated tryptophan metabolic pathways.

公开(公告)号：EP4403167A1

公开(公告)日：2024-07-24

申请号：EP21957132.0

申请日：2021-09-17

申请人： Hinova Pharmaceuticals Inc.

发明人： WEI, Xing ,  KUANG, Tongtao ,  CHEN, Jiang ,  AI, Chaowu ,  LI, Xinghai

IPC分类号： A61K9/22 ,  C07D215/36 ,  C07D215/06 ,  C07D215/42 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/4375 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61P19/06

CPC分类号： A61K9/20 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/4375 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61P19/06 ,  C07D215/06 ,  C07D215/36 ,  C07D215/42

摘要： Disclosed in the present invention is a quinoline compound sustained-release tablet, which contains the following raw and auxiliary materials in parts by weight: 1-40 parts of a quinoline compound, 100-300 parts of a filler, 50-200 parts of a sustained-release material and 0.5-4 parts of a lubricant. The filler comprises, but is not limited to, mannitol, microcrystalline cellulose, lactose, starch, corn starch, calcium hydrogen phosphate hydrate, magnesium carbonate, calcium carbonate, purified sucrose and/or glucose; the sustained-release material comprises, but is not limited to, hydroxypropyl methylcellulose, hydroxypropyl cellulose, and povidone, glyceryl behenate, and/or a long-chain fatty acid; and the lubricant comprises, but is not limited to, magnesium stearate, calcium stearate, sucrose fatty acid ester, sodium stearyl fumarate, polyethylene glycol, talc, glyceryl behenate and/or stearic acid.

公开(公告)号：EP4378936A1

公开(公告)日：2024-06-05

申请号：EP22848701.3

申请日：2022-07-29

申请人： Hinova Pharmaceuticals Inc.

发明人： DU, Wu ,  LI, Xinhai ,  WEN, Kun ,  QIN, Dekun ,  ZHANG, Shaohua ,  CHEN, Song ,  DUAN, Jingyi ,  LV, Haibin ,  LI, Haibo ,  LI, Yu ,  HE, Jinyun ,  CHEN, Muyang ,  LIU, Shijuan ,  FU, Yiwei ,  GUAN, Yikai ,  TU, Zhilin

IPC分类号： C07D401/04 ,  C07D401/14 ,  A61K31/496 ,  A61K31/4439 ,  A61P35/00

CPC分类号： A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/519 ,  A61P11/00 ,  A61P17/10 ,  A61P17/14 ,  A61P31/14 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/10 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D491/107 ,  C07D498/04 ,  C07D519/00 ,  C07D401/04 ,  A61K31/4439

摘要： A compound as shown in formula I, or an optical isomer thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a tautomer thereof, a mesomer thereof, a racemate thereof, an enantiomer thereof, a diastereomer thereof, a mixture form thereof, a metabolite thereof, a metabolic precursor thereof, or an isotope substitute form thereof. TB is a target recognition/binding portion, L is a linking portion, and U is a ubiquitin protease recognition/binding portion, the three portions being connected by means of chemical bonds. The compound can significantly down-regulate mutated androgen receptor (AR) proteins, and has good inhibitory activity on prostate cancer cell lines. The compound of formula I can be used for preparation of a protein degradation targeted chimera for targeted regulation of androgen receptors, and a drug for treating diseases correlated with regulation by androgen receptors, and has particularly good application prospects in drugs for treating prostate cancers and breast cancers.

公开(公告)号：EP4043458A1

公开(公告)日：2022-08-17

申请号：EP20868375.5

申请日：2020-09-25

申请人： Hinova Pharmaceuticals Inc.

发明人： FAN, Lei ,  WANG, Fei ,  WU, Xiaoquan ,  XU, Kexin ,  LUO, Tongchuan ,  ZHANG, Shaohua ,  HUO, Yongxu ,  LI, Xinghai ,  CHEN, Yuanwei

IPC分类号： C07D413/14 ,  C07D471/04 ,  A61K31/422 ,  A61P35/00

摘要： An EP300/CBP inhibitor; specifically provided is a compound as shown in formula I, or a deuterated product thereof, or a salt thereof, or a conformational isomer thereof, or a crystal form thereof, or a solvate thereof. The compound is highly selective for EP300/CBP, and can effectively inhibit the activity of EP300/CBP; in addition, the compound has an excellent inhibitory effect on various tumor cells including prostate cancer cells, leukemia cells, breast cancer cells and multiple myeloma cells. The compound has broad application prospects in the preparation of an EP300/CBP inhibitor, and drugs for preventing and/or treating tumors, myeloid hematopoietic stem/progenitor cells malignant disease, and regulating regulatory T cells.

公开(公告)号：EP3792257A1

公开(公告)日：2021-03-17

申请号：EP19798903.1

申请日：2019-05-06

申请人： Hinova Pharmaceuticals Inc.

发明人： DU, Wu ,  LI, Yu ,  WEN, Kun ,  LI, Xinghai ,  CHEN, Yuanwei

IPC分类号： C07D403/12 ,  A61K31/506 ,  A61P35/00

摘要： Provided are a compound as shown in formula (I) or optical isomers, pharmaceutically acceptable salts, hydrates or solvates thereof, wherein R 1 -R I8 are independently selected from hydrogen and deuterium respectively, but not all of them are hydrogen at the same time. The compound and salts, hydrates or solvates thereof can be used as FAK inhibitors, and used in the preparation of anti-cancer drugs, and compared with the non-deuterated control compound Defactinib, the compound has significantly improved metabolic stability and pharmacokinetic properties, while also possessing good application prospects.